Hereditary Fructose Intolerance: A Comprehensive review

Sumit Kumar Singh, Moinak Sen Sarma

Abstract
Hereditary Fructose Intolerance (HFI) is a rare autosomal recessive inherited disorder that occurs due to the mutation of enzyme aldolase B (ALDOB) located on chromosome 9q22.3. A fructose load leads to the rapid accumulation of fructose 1-phosphate and manifests with its downstream effects. Most commonly children are affected with gastrointestinal symptoms, feeding issues, aversion to sweets and hypoglycemia. Liver manifestations include an asymptomatic increase of transaminases, steatohepatitis and rarely liver failure. Renal involvement usually occurs in the form of proximal renal tubular acidosis and may lead to chronic renal insufficiency. For confirmation, a genetic test is favoured over the measurement of aldolase B activity in the liver biopsy specimen. The crux of HFI management lies in the absolute avoidance of foods containing fructose, sucrose, and sorbitol (FSS). There are many dilemmas regarding tolerance, dietary restriction and occurrence of steatohepatitis. Patients with HFI who adhere strictly to FSS free diet have an excellent prognosis with a normal lifespan. This review attempts to increase awareness and provide a comprehensive review of this rare but treatable disorder.

INTRODUCTION
Fructose is a monosaccharide found in honey, fruits and many vegetables consumed daily. It is also the component of the main sweetening agent, sucrose in the majority of
sweets and syrups. Small amounts of fructose are also produced in the human brain via the polyol pathway (1). After ingestion, fructose is absorbed from the intestine through glucose transport proteins (GLUT) 5 and 2 (2). Subsequent metabolism is carried out predominantly in the liver, kidney and small intestine by the enzymes fructokinase, aldolase B, and triokinase (3). Hereditary fructose intolerance (HFI) is a pathological condition that occurs due to a deficiency of enzyme aldolase B (3). It is characterized by hypoglycemia, lactic acidosis, hypophosphatemia, hyperuricemia, hypermagnesemia and hyperalanemia due to dysregulation of gluconeogenesis, glycogenolysis and decreased inorganic phosphate (4).

**EPIDEMIOLOGY AND GENETICS**

HFI is a rare autosomal recessive inherited disorder with an estimated population prevalence ranging from 1 in 20,000 to 1 in 60,000 (5). There is no sex predilection. The gene for the enzyme aldolase B (ALDOB) is located on chromosome 9q22.3. Mutational aberrations include simple missense mutations, deletions, frameshift mutations, and mutations at splicing sites. A systemic review was conducted to assess ALDOB gene variants among patients with HFI (6). The prevalence of HFI was estimated from the carrier frequency of variants described in patients, as well as rare variants predicted as pathogenic by *in silico* tools. *In silico* predictive software allows assessing the effect of amino acid substitutions on the structure or function of a protein without conducting functional studies (7). The application of in silico tools can significantly improve the detection of genes and variation (8). The studies included in the systematic review described 1426 alleles involved in the pathogenesis of HFI, spread in 29 countries on four continents (6). 68 variants in ALDOB were identified among patients with HFI distributed in different populations. These variants were detected in 85 different genotypic combinations. Most of the mutations described in patients with HFI are restricted to a single ethnic group. The commonest variants distributed worldwide that account for most of the identified cases are:

NM_000035_3:c.178C>T, NP_000026.2:p.(Arg60Ter); NM_000035_3:c.360_363del,
NP_000026.2:p.(Asn120LysfsTer32); NM_000035.3:c.448G>C, NP_000026.2:p.(Ala150Pro); NM_000035.3:c.524C>A, NP_000026.2:p.(Ala175Asp) and NM_000035.3:c.1005C>G, NP_000026.2:p.(Asn335Lys).

The analyses showed that the variants p.(Ala150Pro) and p.(Ala175Asp) are the most frequent in patients, accounting for approximately 68% of the alleles. The p.(Ala150Pro) variant alone accounts for 53% of all alleles identified worldwide, and has a variable frequency between the different geographic regions. p.(Asn120LysfsTer32) variant is the third most frequent (4.6%) (9-11). Five novel mutations, (c.324+1G>A, c.112+1delG, c.380-1G>A, c.677G>A, and c.689delA) have been reported from an Indian community (12).

**PATHOGENESIS**

It carries out the reversible conversion of fructose 1-phosphate (F-1P) to Glyceraldehyde (GAH) and dihydroxyacetone phosphate (DHAP) as shown in figure 1. Aldolase B also plays a role in gluconeogenesis and glycolytic pathways as it catalyzes fructose 1,6-bisphosphate (F-1,6P2) conversion to DHAP and glyceraldehyde 3-phosphate (G3P) in a reversible manner (fig 1). There are two other isoenzymes, aldolase A (predominantly expressed in skeletal muscle and red blood cells) and aldolase C (predominantly expressed in brain and smooth muscle) and both have a high affinity for F-1,6-P2 as a substrate (13). The deficiency of aldolase A manifests mainly as recurrent rhabdomyolysis which may sometimes be accompanied by hemolysis and termed glycogen storage disorder type 12. (14-15). Aldolase C expression has been found to be associated with certain neuroendocrine tumors and is being studied as a marker of neuroendocrine tumors (16).

Metabolic consequences: In a patient with HFI, a fructose load leads to the rapid accumulation of F-1P which results in depletion of intracellular inorganic phosphate (Pi) and adenosine triphosphate (ATP). As a result, adenosine 5’-monophosphate (AMP) degradation is increased, and hence, inosine monophosphate (IMP) and urate are generated rapidly resulting in hyperuricemia which is responsible for gout in
patients with HFI (Figure 1). Increased IMP through specific inhibition of aldolase B creates a vicious cycle leading to a further increase in F-1P. Depletion of ATP also results in increased release of magnesium as well as impaired protein synthesis and ultrastructural lesions which are responsible for hepatic and renal dysfunction. The consequences of increased F-1P are shown in figure 2.

Increased F-1P along with reduced Pi is also responsible for inhibition of glycogenolysis through impairment of glycogen phosphorylase. This fructose-induced hypoglycemia in HFI is not corrected by the administration of exogenous glucagon which again emphasizes the impaired glycogenolysis pathway. Further, the accumulation of F-1P impeded gluconeogenesis by inhibition of glucose-6-phosphate isomerase (G6P) (Fig 1). Overall, when a patient with HFI is given a fructose load, it leads to hypoglycemia due to deranged gluconeogenesis and glycogenolysis. In addition, lactic acidosis occurs due to activation of glycolytic pathway through increased activity of pyruvate kinase by F-1P and inability of aldolase B to convert DHAP and G3P to F-1,6P2. Notably, the metabolic consequences of fructose load also occur after ingestion of sorbitol found in various syrups and those with high glycemic foods such as rice. Sorbitol, through polyol pathways, is responsible for the endogenous production of fructose (fig 1) (1).

**CLINICAL FEATURES**

The genotype-phenotype correlation has not been identified in patients with HFI. Patients with HFI develop symptoms only when exposed to dietary fructose directly or indirectly through sucrose or sorbitol. The classical presentation is described as an infant, otherwise healthy, presenting with nausea, protracted vomiting, poor feeding and lethargy and sometimes with seizures following the introduction of weaning foods containing sugar or starch (17). Li et al reported four cases of neonatal and early infantile acute liver failure associated with multi-organ failure induced by sucrose-containing common infant formula in patients with undiagnosed HFI (18). All patients were appropriately grown, born at term after uncomplicated pregnancies and deliveries, and discharged within the first week of life. There was no known
consanguinity. One patient had a family history of an older brother who died on day 28 of life with a similar illness, though a specific diagnosis could not be ascertained. Another patient had a maternal half-sister who required a liver transplant for an indeterminate liver failure. Careful dietary history was obtained in all infants, though fructose exposure was unclear in two of the 4 cases due to unreliable history or unclear ingredient labelling, which delayed diagnosis. In all four cases, the newborn screen was normal. The diagnosis was confirmed by ALDOB gene sequencing. All infants were homozygous for the common c.448G > C (p.A150P) pathogenic variant (18). Sometimes, it may present late in childhood or adulthood owing to the self-imposed strict dietary restriction of fructose-containing food items(19-20). The child shows a strong aversion to sweets.

An intermittent dietary restriction can have a subtle presentation in the form of isolated hepatomegaly or intermittent elevations in transaminases(21). Thus, a dietary history of fructose intake and the presence of fatty liver are important clues to suspect an underlying HFI in infants. Chronic liver disease in form of fatty liver, steatohepatitis and even cirrhosis may occur in patients with HFI who are fed regularly on a fructose-rich diet. Examination typically shows growth failure and hepatomegaly with or without jaundice. Renal involvement usually occurs in the form of proximal renal tubular acidosis and may lead to chronic renal insufficiency. Metabolic derangements include hypoglycemia, lactic acidosis, hypophosphatemia, hyperuricemia and hypermagnesemia(6). HFI presenting as relapsing acute axonal neuropathy has also been reported recently, which improves after dietary fructose omission(22).

In contrast to the classical presentation of the above acute symptoms, some patients with residual enzymatic activity may remain asymptomatic or require a larger burden of fructose to become symptomatic. HFI can also remain masked in the presence of concomitant diseases. Aldag et al reported an infant developing unexplained liver failure and metabolic dysfunction soon after a successful pyloromyotomy for hypertrophic pyloric stenosis and the diagnosis was confirmed by genetic testing. (23). Similarly, Bobrus-Chociej reported that elevated transaminases and fatty liver may
continue to prevail despite a compliant gluten-free diet in patients with celiac disease. In such a situation, a strong degree of suspicion for HFI is required (24). Heterozygotes with HFI do not present with classical manifestations of HFI. It has been shown that there are significant but occult metabolic derangements in HFI heterozygous carriers. Randomized cross-over trials show that a high fructose diet (1.4g/kg/day) increased postprandial plasma uric acid, insulin and hepatic insulin resistance index as compared to those on a low fructose diet (<10 g/day). This analysis provides insight as to the extent of metabolic damages that can take place in homozygotes in whom these trials are deemed unethical (25). There are several reports of gouty arthritis due to hyperuricemia in children with heterozygous mutation for HFI (26).

**EVALUATION**

A meticulous history revealing a clear correlation between exposure to dietary fructose and the onset of symptoms is the key to suspecting the possibility of underlying HFI. There are various pitfalls in the diagnosis of HFI. Kim *et al* in their case series of 5 patients with subtle symptoms and aversion to sweets. They make a pertinent point that emphasis of classic teaching on infantile acute liver failure and biochemical derangements, such as hypoglycemia and hypophosphatemia, after the first exposure to fructose may inadvertently increase the likelihood of missing cases of HFI characterized by other manifestations. Hence index of suspicion must be high and wide screening must be employed. HFI should be looked for in any patient with unexplained reasons for failing to thrive. HFI is also often misdiagnosed with other nongenetic and genetic conditions, including an eating disorder, recurrent hepatitis, and glycogen storage disease. Moreover, fructose intolerance may not be pathognomonic for HFI alone, given the description of rare patients with fruit-induced, food protein-induced enterocolitis syndrome (27). Furthermore, the lack of a specific and practical biomarker for HFI means that neither newborn screening nor biochemical testing can be used to establish
the diagnosis. Compliance, discrimination and psychosocial issues may be specific problems in adolescence (28).
Detection of non-glucose-reducing substances in the urine sample while on a fructose-containing diet is a bedside screening test. The presence of reducing sugars (glucose/fructose/Lactose) in urine can be detected by Benedict’s test (29). While glucose can be detected in urine by glucose dipsticks, a positive Benedict’s test in urine with a negative glucose dipstick test points to the presence of other reducing sugars like fructose/Lactose. Provocative fructose tolerance tests in young children are cumbersome and fraught with the dangers of hypoglycemia. Are there simpler biochemical ways to screen for HFI? Untreated HFI patients present abnormal transferrin (Tf) glycosylation patterns due to the inhibition of mannose-6-phosphate isomerase by fructose-1-phosphate. Hence, elevated serum carbohydrate-deficient Tf (CDT) may allow the prompt detection of HFI. The CDT values improve when an F5S-restrictive diet is followed. Cano et al showed that by capillary zone electrophoresis method, asialoTf correlated with dietary intake of sucrose and that pentasialoTf+hexasialoTf negatively correlated with dietary intake of fructose in patients with HFI. Moreover, the tetrasialoTf/disialoTf ratio also differentiated treated HFI patients from healthy controls (30). However some patients with HFI have been initially misdiagnosed with type 1 congenital disorders of glycosylation (31).
Liver biopsy in patients with HFI shows macrovesicular steatosis with or without changes in inflammation and fibrosis (32). For confirmation, a genetic test is favoured over the measurement of aldolase B activity in liver biopsy specimens as later is invasive and not widely available. Genetic testing has high sensitivity and specificity and includes single gene sequencing, multi-gene panels, and genomic testing (33).

**DIFFERENTIAL DIAGNOSIS**
Acute presentation of HFI mimics sepsis, acute infectious hepatitis, hemophagocytic lymphohistiocytosis and other metabolic diseases such as galactosemia, tyrosinemia, organic academia and urea cycle defect. In children presenting with hepatomegaly,
fatty liver and raised transaminases, possibilities of Wilson disease, glycogen storage disorder, alpha-1 antitrypsin deficiency should be considered. Presentation as hypoglycemia, acidosis and hepatomegaly mimic fructose 1,6 bisphosphate deficiency, beta-ketothiolase deficiency, pyruvate carboxylase deficiency, congenital disorder of glycosylation, fatty acid oxidation defects and milder variants of respiratory chain defects. Predominant gastrointestinal symptoms and aversion to sweets distinguish HFI from the rest of the differential diagnoses.

**TREATMENT**

Being a complex metabolic disorder, management of HFI needs a multidisciplinary approach with the involvement of a pediatrician, clinical geneticist, dietician with experience in metabolic disorders, hepatologist and nephrologist. The crux of HFI management lies in the absolute avoidance of foods containing fructose, sucrose, and sorbitol (FSS). Patients presenting with an acute metabolic crisis should be admitted to an intensive care setting and initiated intravenous glucose(dextrose), treatment of metabolic acidosis, (if present) and supportive treatment. Strict avoidance of FSS in the diet along with supplementation of other sources of carbohydrate (glucose, corn-starch) results in rapid reversal of symptoms. At length repetitive counselling, clear instructions on dietary restrictions and continuous reinforcement are required to maintain long-term dietary compliance and precipitations of break-through events. Table 1 enlists the food items which should be avoided and which are permitted in patients with HFI. Patients with HFI on a strict FSS elimination diet can develop several nutritional deficiencies, especially vitamins mainly Vitamin C found predominantly in fruits and vitamin B complex. Thus, it is recommended to add multivitamin supplements to prevent the consequences of these deficiencies (34).

**CONTROVERSIES IN MANAGEMENT:**

*Diet:* Although a strict FSS diet is recommended while treating HFI, there is no clarity as to whether small amounts of fructose can be tolerated in the diet. At what permissible
limit of fructose will liver and kidney damage not occur? Restriction of FSS may lead to growth failure even in clinically asymptomatic HFI patients. There is insufficient information about the long-term outcomes of minimal fructose ingestion. A recent study from Italy reported the ten years of follow-up of patients with HFI. Fatty liver (on sonography) persisted in 93.8% of patients despite being on FSS restricted diet of <1.5g/d (35). The authors also found that a significant proportion of patients continued to have raised transaminases (37.5%) even when dietary compliant. There are two reasons for the persisting liver abnormalities in patients with HFI. Firstly, fructose may be endogenously produced by the sorbitol-aldose reductase pathway, which can be activated after a glucose-enriched meal, nephrotoxic drugs or stressful conditions like sepsis and major surgery. Secondly, the permissible limits of fructose ingestion may not be safe in asymptomatic patients of HFI. The latter is supported by the determination of carbohydrate-deficient transferrin (CDT) by isoelectric focusing among the patients with HFI on an FSS-free diet by Di Dato et al(35). They showed a significant correlation between the amount of fructose consumed and the percentage of disialoTf and tetrasiakoTf/disialoTf ratio. The authors suggested that serum CDT profile could be considered a good tool to monitor FSS intake. In addition, CDT determination could be used to identify the maximum daily fructose tolerability of each HFI patient. However, the lack of widespread availability and high cost are the main barriers to the application of this tool.

*Non-alcoholic fatty liver disease (NAFLD) and HFI:* As evident from the study by Di Dato et al, the majority of the patients with HFI despite being on an FSS-free diet continued to have fatty liver (35). In another cross-sectional study of 16 patients, NAFLD was found in 9 (56%) patients (32). The importance lies in the fact that fatty liver may progress to steatohepatitis, hepatic fibrosis and cirrhosis. Moreover, there is an increased risk of type 2 diabetes and cardiovascular diseases(36,37). The studies in ALDOB-KO mice as well as in patients with HFI have demonstrated that NAFLD may not be the result of direct lipogenic effects of fructose(38, 39). In addition, when ALDOB-KO mice were chronically exposed to small amounts of fructose in the chow (~ 0.3%), they showed an
increased accumulation of hepatic triglycerides, hepatic inflammation and signs of periportal fibrosis (38, 40). Notably, these ALDOB-KO mice also had increased intrahepatic F-1P concentrations (38). Lanaspa et al also showed the increased hepatic expression of enzymes was seen in de novo lipogenesis with an abundance of cytosolic glucokinase in ALDOB-KO mice (38). Thus, it can be speculated that the accumulation of F-1P in ALDOB-KO mice may stimulate hepatic glucose uptake, thereby enhancing the storage of glycogen and fat.

In the experimental model, almost all the metabolic abnormalities in the ALDOB-KO mice were ameliorated when supplemented with ketoheoxokinase (KHK), an enzyme involved in the phosphorylation of fructose (38). Treatment with osthole, a natural KHK inhibitor also showed the same results (41). Additionally, osthole treatment inhibited de novo lipogenesis in ALDOB KO mice. In humans, a loss of KHK results in essential fructosuria (OMIM #229800) which is a benign condition (42). Hence, KHK inhibition may serve as a potential therapeutic target for the treatment of NAFLD in patients with HFL. Ghanem et al have unusually reported epithelioid granulomas in association with liver adenomatosis and macrovesicular steatosis in an adult with HFI that yielded negative workup for tuberculosis, sarcoidosis and other infectious diseases. They postulated that the granulomas in the non-tumour liver sections may have developed from the inflammatory stress due to inflammatory hepatocellular adenomas. (43)

Vaccines: There are considerable controversies about the safety concerns of vaccines that contain fructose, sucrose or sorbitol in HFI. Saborido-Fiaño et al argue that the safe threshold of fructose was 2.4 mg/kg/dose and various oral rotavirus vaccines would not qualify for that category. (44,45) This requires the need to revisit the vaccine content. The authors also cautioned against the use of Sars-Cov-2 vaccines in children affected with HFI. Urro et al demonstrated the safety of these vaccines in adults (46).

PROGNOSIS
The data on long-term follow-up of patients with HFI is not available in the literature. However, In a recent study of HFI children with a mean follow-up of 10.3± 5.6 years, all
of them were asymptomatic but had evidence of fatty liver in the majority and raised transaminases in some of them (26). Interestingly, fructose intake in these children did not correlate with either of the two findings. The two case reports of HFI being diagnosed in adulthood because of self-imposed restriction to fructose in the diet since infancy may signify that the patients with HFI who adhere strictly to an FSS-free diet may have a good prognosis and normal lifespan (19,20). On the other hand, when compliance is poor, renal and liver-related complications in the form of chronic renal insufficiency and hepatic fibrosis may ensue.

FUTURE RESEARCH
There is a need for data on the long-term outcome of HFI patients on an FSS-restricted diet to provide more insights into the consequences of NAFLD, cardiovascular disease and type 2 diabetes. Recent studies emphasized the role of F-1P in the hepatic fat accumulation of ALDOB-KO mice and the development of NAFLD. However, the exact role of endogenous fructose production (via the polyol pathway) in the accumulation of intrahepatic F-1P remains to be determined in animals as well as humans. Finally, clinical trials are required to show the benefit of KHK inhibition in the treatment of NAFLD in HFI patients.

CONCLUSION
HFI has diverse manifestations involving gastrointestinal, liver and renal issues. It mimics many metabolic conditions which present similarly. Other than genetics, there are no reliable laboratory markers that effectively diagnose this condition. A straightforward FSS-free diet generally leads to a good long-term prognosis. There are however considerable controversies on the effect of dietary therapy on the liver, biochemistry, coexistence of steatosis and permissible levels of fructose in vaccines. Future research should be directed to basic sciences and long-term outcomes of this disease.

Hong Li, Heather M. Byers, Alicia Diaz-Kuan, Miriam B. Vos et al. "Acute liver failure in neonates with undiagnosed hereditary fructose intolerance due to exposure from widely available infant formulas", Molecular Genetics and Metabolism, 2018

pediatrics.aappublications.org


link.springer.com

www.mdpi.com

www.x-mol.com


Www.statpearls.com